Literature DB >> 15880807

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

Trond Ove R Hjelmervik1, Kjell Petersen, Inge Jonassen, Roland Jonsson, Anne Isine Bolstad.   

Abstract

OBJECTIVE: To identify gene expression signatures in minor salivary glands (MSGs) from patients with primary Sjogren's syndrome (SS).
METHODS: A 16K complementary DNA microarray was used to generate gene expression profiles in MSGs obtained from 10 patients with primary SS and 10 control subjects. The data were analyzed by 2 different strategies, one strict primary analysis and one subanalysis that allowed for inclusion of genes with no signal in more than 3 samples from each group. The results were validated by quantitative reverse transcriptase-polymerase chain reaction techniques.
RESULTS: We found a distinct difference in gene expression levels in MSGs, enabling a simple class prediction method to correctly classify 19 of the 20 samples as either patient or control, based on the top 5 differentially expressed genes. The 50 most differentially expressed genes in the primary SS group compared with the control group were all up-regulated, and a clear pattern of genes involved in chronic inflammation was found. CXCL13 and CD3D were expressed in >/=90% of primary SS patients and in </=10% of the controls. Lymphotoxin beta, as well as a number of major histocompatibility complex genes, cytokines, and lymphocyte activation factors, manifested its role in the pathogenesis of SS. Numerous type I interferon genes related to virus infection were found among the top 200 genes, with increased expression in primary SS. Interestingly, the expression of carbonic anhydrase II, which is essential in saliva production and secretion, and the apoptosis regulator Bcl-2-like 2 were down-regulated in primary SS patients.
CONCLUSION: We have identified distinct gene expression profiles in MSGs from patients with primary SS that provide new knowledge about groups of genes that are up-regulated or down-regulated during disease, constituting an excellent platform for forthcoming functional studies.

Entities:  

Mesh:

Year:  2005        PMID: 15880807     DOI: 10.1002/art.21006

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  119 in total

1.  Preclinical validation of salivary biomarkers for primary Sjögren's syndrome.

Authors:  Shen Hu; Kai Gao; Rodney Pollard; Martha Arellano-Garcia; Hui Zhou; Lei Zhang; David Elashoff; Cees G M Kallenberg; Arjan Vissink; David T Wong
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-08       Impact factor: 4.794

2.  Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome.

Authors:  Juan Wang; Huiyong Peng; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Yungang Wang; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 3.  Interferon-γ and systemic autoimmunity.

Authors:  Kenneth M Pollard; David M Cauvi; Christopher B Toomey; Kevin V Morris; Dwight H Kono
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

4.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 5.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

6.  Lymphoma and other malignancies in primary Sjögren's syndrome.

Authors:  S R Pillemer
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

7.  Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.

Authors:  Barbara M Segal; Abu N M Nazmul-Hossain; Ketan Patel; Pamela Hughes; Kathy L Moser; Nelson L Rhodus
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-04-16

8.  CXCL13 levels in serum but not in saliva are elevated in Asian Indian patients with primary Sjögren's syndrome.

Authors:  Santosh Kumar Mandal; Pulukool Sandhya; Jayakanthan Kabeerdoss; Janardana Ramya; Gowri Mahasampath; Debashish Danda
Journal:  Rheumatol Int       Date:  2018-03-14       Impact factor: 2.631

9.  Distinct Regulation of CXCL10 Production by Cytokines in Human Salivary Gland Ductal and Acinar Cells.

Authors:  Keiko Aota; Koichi Kani; Tomoko Yamanoi; Koh-Ichi Nakashiro; Naozumi Ishimaru; Masayuki Azuma
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

10.  Type I interferon receptor deficiency prevents murine Sjogren's syndrome.

Authors:  B M Szczerba; P D Rybakowska; P Dey; K M Payerhin; A B Peck; H Bagavant; U S Deshmukh
Journal:  J Dent Res       Date:  2013-03-26       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.